Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 36, 2001 - Issue 12
Submit an article Journal homepage
10
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Biotechnologically Manufactured Drugs for Inflammatory Bowel Disease

J. A. Petersen, S. Nørby Rasmussen
Pages 1233-1238 | Published online: 08 Jul 2009

  • Wu-Pong S. An overview of biotechnology. In: Wu-Pong S, Rojanasakul Y, editors. Biopharmaceutical drug design and development, 1st ed. New Jersey: Humana Press; 1999. p. 3-10.
  • Steinberg FM, Raso J. Biotech pharmaceutical s and biotherapy : an overview. J Pharm Pharm Sei 1998;1:48-59.
  • Walsh G. Biopharmaceutical benchmarks. Nat Biotechnol 2000:18:831-3.
  • Askari FK, McDonell WM. Antisense-oligonucleotid e therapy. N Engl J Med 1996;334:316-8.
  • Lysik M, Wu-Pong S. Oligonucleotides and ribozymes. In: Wu-Pong S, Rojanasakul Y, editors. Biopharmaceutical drug design and development, 1st ed. New Jersey: Humana Press; 1999. p. 143-85.
  • Seder RA, Gurunathan S. DNA vaccines--designer vaccines for the 21st century. N Engl J Med 1999;341:277-8.
  • Datum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston AM, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999;17: 666-9.
  • Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993:14:243-6.
  • Kompella UB. Protein drug delivery. In: Wu-Pong S, Rojanasakul Y, editors. Biopharmaceutical drug design and development, 1st ed. New Jersey: Humana Press; 1999. p. 256-7.
  • Hedley ML. Gene therapy of chronic inflammatory disease. Adv Drug Deliv Rev 2000;44:195-207.
  • Shanahan F. Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflam Bowel Dis 2000;6:107-15.
  • Fiocchi C. Inflammatory bowel disease. Gastroenterology 1998; 115:182-205.
  • Hanauer SB, Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
  • Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337: 1029-35.
  • Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
  • Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized doubleblind placebo-controlled trial. Gastroenterology 2001 ;120: 1330-8.
  • Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349:521-4.
  • Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Lloyd R, et al. A randomized, double-blind, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn's disease. Gastroenterology 2000;118:A655.
  • Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-á monoclonal antibody cA2 binds recombinant transmembrane TNF-á and activates immune effector functions. Cytokine 1995;7:251-9.
  • D'Haens G, Swijsen C, Norman M, Lemmens L, Geboes K, Rutgeerts P. Etanercept (TNF receptor fusion protein, Enbrel) is effective and well tolerated in active refractory Crohn's disease: results of a single center pilot trial. Gastroenterology 2000;118: A656.
  • Sandborn JW, Hanauer SB, Katz S, Safdi M, Wolf DC, Baerg RD, et al. A randomized, double-blind, placebo-controlled trial of subcutaneous etanercept (p75 soluble tumor necrosis factor: FC fusion protein) in the treatment of moderate to severe Crohn's disease. Gastroenterology 2001;120:A20.
  • Van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997; 113:383-9.
  • Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams CN, Nikolaus S, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000:119:1461-72.
  • Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000;119:1473-82.
  • Peterson RL, Wang L, Albert L, Keith JC, Domer AJ. Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 1998;78: 1503-12.
  • Qiu BS, Pfeiffer CJ, Keith JC. Protection by recombinant human interleukin-1 1 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996:41:1625-30.
  • Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58-64.
  • Van Assche G, Dalle I, Noman M, Aerden I, Swijsen C, Macs B, et al. The use of humanized, anti-interleukin-2 receptor antibodies (Zenapax, Roche) in refractory ulcerative colitis. Gastroenterology 2001; 120:A279.
  • Salmi M, Jalkanen S. Molecules controlling lymphocyte migration to the gut. Gut 1999;45:148-53.
  • Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1 ; CD 54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996;23:1338-44.
  • Henry SP, Templin MV, Gillet N, Rojko J, Levin AA. Correlation of toxicity and pharmacokmetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-I. Toxicol Pathol 199927:95-100.
  • Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al. A placebo-controlled trial of ICAM-I antisense oligonucleotid e in the treatment of Crohn's disease. Gastroenterology 1998;114:1133-42.
  • Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al. Absence of efficacy of subcutaneous antisense ICAM-I treatment of chronic active Crohn's disease. Gastroenterology 2001;120:1339-46.
  • Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchmann AL, et al. A randomized, placebo-controlled trial of an antisense ICAM-1 inhibitor (ISIS 2302) in steroiddependent Crohn's disease showed clinical improvement at high serum levels. Gastroenterology 2001;120:A279.
  • Gordon FH, Lai CWY, Hamilton MI, Allison MC, Fourweather M, Donoghue S. Randomised double-blind placebo-controlled trial of recombinant humanised antibody to a4 integrin (Antegren) in active Crohn's disease. Gastroenterology 1999; 116:A726.
  • Gordon FH, Lai CWY, Hamilton MI, Allison MC, Fourweather M, Donoghue S. Treatment of active ulcerative colitis with a recombinant humanised antibody to a4 integrin (Antegren). Gastroenterology 1999;116:A726.
  • Ghosh S, Goldin E, Malchow HA, Pounder RE, Rask-Madsen J, Rutgeerts P, et al. A randomised, double-blind, placebocontrolled, pan-European study of a recombinant humanised antibody to alpha-4 integrin (Antegren) in moderate to severe active Crohn's disease. Gastroenterology 2001;120:A127.
  • Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge LT, Tytgat GN, et al. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 1997;40: 320-7.
  • Canva-Delcambre V, Jacquot S, Robinet E, Lemann M, Drouet C, Labalette M, et al. Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Aliment Pharmacol Ther 1996; 10:721-7.
  • Deush K, Reiter C, Mauthe B, Riethmüller G, Classen M. Chimeric monoclonal anti-CD4 antibody therapy proves effective for treating inflammatory bowel disease. Gastroenterology 1992;102:A615.
  • Emmrich J, Seyfarth M, Liebe S, Emmrich F. Anti-CD4antibody treatment in inflammatory bowel disease without a long CD4+-cell depletion. Gastroenterology 1995:108:A815.
  • Slonim AE, Bulone L, Damore MB, Goldberg T, Wingertzahn MA, McKinley MJ. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000;342:1633-7.
  • Sinha A, Nightingale JM, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas are effective in the treatment of left-sided ulcerative colitis. Gastroenterology 2001; 120:A11.
  • Korzenik JR, Dieckgraefe BK. Immune stimulation in Crohn's disease: safety and efficacy of rhu GM-CSF for the treatment of active Crohn's disease. Gastroenterology 2001;120:A277.
  • Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease. N Engl J Med 1999;340:239-40.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.